

Figure S1 Survival outcomes in patients with high/low TMB in early-stage NSCLC using clinical cutoffs and selected cutoffs. Kaplan-Meier survival plots of NCSLC patients stratified by TMB at clinical a cutoff of 10 and selected cutoffs based on output from the maxStat R package. Below each Kaplan-Meier plot is a risk table showing the number of at-risk individuals in each group over time. P values were adjusted when multiple comparisons were performed using the false discovery control rate via SciPy Stats python package and are labeled P_{adj} on the plot. (A) Early-stage LUSC PFS stratified by TMB >10. (B) Early-stage LUSC OS stratified by TMB >10. (C) Early-stage LUAD PFS stratified by TMB >10. (D) Early-stage LUAD OS stratified by TMB >10. (E) Early-stage LUSC PFS stratified by TMB >4. (F) Early-stage LUSC OS stratified by TMB >4. (G) Early-stage LUAD PFS stratified by TMB >2. (H) Early-stage LUAD OS stratified by TMB >2. P values based on log-rank test and adjusted with false discovery rate control. NSCLC, non-small cell lung cancer; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; PFS, progression-free survival; OS, overall survival; TMB, tumor mutational burden.

https://dx.doi.org/10.21037/tlcr-24-226



Figure 2 Survival outcomes in patients with high TMB in early-stage NSCLC, stratified by ITH using selected cutoffs. Kaplan-Meier survival plots of early-stage NSCLC patients stratified by ITH and high TMB at selected cutoffs based on output from the maxStat R package. Below each Kaplan Meier plot is a risk table showing the number of at risk individuals in each group over time. (A) Early-stage LUSC with high TMB (TMB >9) PFS stratified by ITH >1.4. (B) Early-stage LUSC with high TMB (TMB >9) OS stratified by ITH >1.4. (C) Early-stage LUAD with high TMB (TMB >6) PFS stratified by ITH >2.7. (D) Early-stage LUAD with high TMB (TMB >6) OS stratified by ITH >2.7. P values based on log-rank test. NSCLC, non-small cell lung cancer; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; PFS, progression-free survival; OS, overall survival; TMB, tumor mutational burden; ITH, intratumor heterogeneity.

https://dx.doi.org/10.21037/tlcr-24-226